HLB bioStep Co.,Ltd.: debt-to-equity, ROE and more
KOSDAQ, Legal name HLB bioStep Co.,Ltd.
Latest figures are the FY2025 consolidated summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 54.1%
- Equity ratio
- 64.9%
- ROE
- -20.1%
- Op. margin
- -11.6%
- Rev. growth
- 27.3%
- Interest coverage
- n/a
Condition flags
- Latest operating profit is not above zero, or not reported.
- Operating loss for 3 straight years.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
No dividend data yet for this company.
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 consolidated | 42.6% | 70.1% | 17.4% | 15.3% | n/a |
| FY2022 consolidated | 142.4% | 41.3% | -4.1% | 7.4% | 34.0% |
| FY2023 consolidated | 65.8% | 60.3% | -0.1% | -2.4% | -38.8% |
| FY2024 consolidated | 44.1% | 69.4% | -8.3% | -22.3% | 10.1% |
| FY2025 consolidated | 54.1% | 64.9% | -20.1% | -11.6% | 27.3% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩64.4B | ₩86.3B | ₩52.8B | ₩58.2B | ₩74.1B |
| Operating profit | ₩9.8B | ₩6.4B | -₩1.3B | -₩13.0B | -₩8.6B |
| Pre-tax income | ₩12.8B | -₩2.3B | ₩325.7M | -₩11.5B | -₩17.5B |
| Net income | ₩11.5B | -₩2.9B | -₩54.2M | -₩9.7B | -₩20.3B |
| Total assets | ₩94.6B | ₩170.2B | ₩171.7B | ₩168.3B | ₩155.6B |
| Total liabilities | ₩28.3B | ₩100.0B | ₩68.1B | ₩51.5B | ₩54.6B |
| Total equity | ₩66.4B | ₩70.2B | ₩103.6B | ₩116.8B | ₩100.9B |
| Paid-in capital | ₩765.2M | ₩7.1B | ₩7.9B | ₩8.7B | ₩8.7B |
| Debt/equity (source value) | 42.6% | 142.4% | 65.8% | 44.1% | 54.1% |
Company outline (FSC)
- Market
- KOSDAQ
- Fiscal year end
- Dec
- Founded
- 2012-04-19
- Listed
- 19/11/27
- Employees
- 150
- Auditor
- 삼정
- Audit opinion
- 적정의견
- Corporate reg. no.
- 2842110063231
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for HLB바이오스텝Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.